Northwest Biotherapeutics (NWBO) EBIAT (2016 - 2025)
Historic EBIAT for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$26.8 million.
- Northwest Biotherapeutics' EBIAT fell 3847.94% to -$26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.8 million, marking a year-over-year decrease of 2911.03%. This contributed to the annual value of -$83.8 million for FY2024, which is 3383.28% down from last year.
- Latest data reveals that Northwest Biotherapeutics reported EBIAT of -$26.8 million as of Q3 2025, which was down 3847.94% from -$15.4 million recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' EBIAT ranged from a high of $133.3 million in Q4 2021 and a low of -$32.9 million during Q3 2022
- Its 5-year average for EBIAT is -$7.0 million, with a median of -$17.9 million in 2024.
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 14756.35% in 2021, then crashed by 77274.38% in 2022.
- Northwest Biotherapeutics' EBIAT (Quarter) stood at $133.3 million in 2021, then crashed by 121.23% to -$28.3 million in 2022, then soared by 50.61% to -$14.0 million in 2023, then plummeted by 101.92% to -$28.2 million in 2024, then rose by 4.94% to -$26.8 million in 2025.
- Its EBIAT stands at -$26.8 million for Q3 2025, versus -$15.4 million for Q2 2025 and -$19.3 million for Q1 2025.